NDAINHALATIONPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
7/8 — Comprehensive
AIRDUO RESPICLICK (fluticasone propionate and salmeterol) by Teva is salmeterol. Approved for asthma. First approved in 2017.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AIRDUO RESPICLICK is a combination inhaled powder containing fluticasone propionate (a potent corticosteroid) and salmeterol (a long-acting beta-2 agonist) for maintenance treatment of asthma. The corticosteroid reduces airway inflammation while the LABA provides sustained bronchodilation, addressing both inflammatory and bronchial smooth muscle components of asthma pathophysiology.
$0.207MPart D
Peak14.7 years to LOEProduct is at peak lifecycle with modest Part D spending; team focus is on maintaining market share in a competitive ICS/LABA category rather than expansion.
Mechanism of Action
salmeterol. The mechanisms of action described below for the individual components apply to this combination product. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices.…
Worked on AIRDUO RESPICLICK at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.